** Shares of Innovent Biologics Inc 1801.HK rise 2.8% to HK$55.25 on their second session of gain, on track for the biggest one-day pct gain since April 24
** The Chinese innovative medicines developer and producer says it achieved total product revenue exceeding 2.4 bln yuan ($330.10 mln) for the first quarter of 2025, maintaining over 40% year-on-year growth
** "The year 2025 is a significant year for the company as it enters a new era of growth and global innovation" - Innovent
** Hang Seng Biotech Index .HSHKBIO gains 0.8%, Hang Seng Index .HSI rises 1.5%
** Stock up 50.7% YTD
($1 = 7.2706 Chinese yuan renminbi)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。